Clinical outcomes (analyzed as single-group)
depression, depressive symptoms
REGRESSION, EMA
Across doses, analyses will explore changes in clinical outcomes from pre- to post-mbNF. Analyses will examine changes from baseline to the 1-month follow-up in depression symptoms using the self-reports (MFQ) and interviewer assessments (CDRS-R), as well as self-reported rumination using the RRS. Sum scores will be used as outcome measures for the MFQ and RRS. Further analyses will explore changes in EMA reports of depressive symptoms (sum of PHQ-2 EMA items) and rumination (sum of RRS & PTQ EMA items). Change will be examined from pre-mbNF to both the week immediately after and the week of the 1-month follow-up. Clinical outcomes will each be analyzed similarly to primary analyses using linear mixed-effects regression models as follows: